We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » HHS WON'T USE 'MARCH-IN' POWER TO ALLOW GENERIC VERSIONS OF NORVIR
HHS WON'T USE 'MARCH-IN' POWER TO ALLOW GENERIC VERSIONS OF NORVIR
August 10, 2004
The National Institutes of Health (NIH) has denied a request by an advocacy group to break patents on Abbott Laboratories’ AIDS drug Norvir (ritonavir) and authorize generic competition.